METHOD FOR TREATMENT OF PROSTATE GLAND DISEASES BASED ON LOCAL DELIVERY OF ACTIVE MATERIALS Russian patent published in 2010 - IPC A61K9/16 A61K9/22 

Abstract RU 2404747 C2

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of medicine, in particular to urology, and may be used to treat prostate-related diseases of an individual. Initial booster dose of one or more active materials and/or prodrugs are administered to an individual in a non-obligatory manner, and pharmaceutical composition with controlled release including one or more active materials in biodegradable ceramic carrier is locally introduced into prostate gland. Biodegradable hydrating ceramic material may be selected from the group consisting of non-hydrated or hydrated calcium sulfate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulfate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulfate, barium phosphate, barium carbonate, barium fluoride, barium silicate or their mixtures. In a particular version of realisation, biodegradable hydrating ceramic material is non-hydrated or hydrated calcium sulfate. Also a set is used, representing initial booster dose of one or more active materials and/or prodrugs and the second component representing pharmaceutical composition with controlled release including one or more active materials in biodegradable ceramic carrier, and their application.

EFFECT: method provides for maximum therapeutic effect, with considerable reduction of toxicity.

54 cl, 7 tbl, 10 ex, 5 dwg

Similar patents RU2404747C2

Title Year Author Number
BIOLOGICALLY RESOLVING COMPOSITION WITH CONTROLLED RELEASE 2007
  • Aksen Niklas
  • Lennernes Khans
RU2405537C2
METHOD OF TREATMENT OF ANDROGEN ALOPECIA WITH 5-ALPHA-REDUCTASE INHIBITORS 1994
  • Glenn Dzh. Gomli
  • Kejt D. Kaufman
  • Ehlizabet Stoner
  • Dzhoann Val'Dshtrajkher
RU2173152C2
COMBINATION OF THERAPEUTICAL AGENTS (FOR EXAMPLE, CHLOROPROMAZINE AND PENTAMIDINE) FOR TREATING NEOPLASTIC DISORDERS 2001
  • Borajsi Aleksis
  • Kejt Kertis
  • Fouli Majkl A.
  • Stokvell Brent R.
RU2286769C2
OCTREOTIDE IMPLANT CONTAINING RELEASING SUBSTANCE 2009
  • Kuzma Peter
  • Deker Stefani
  • Kuandt Garri
RU2521291C2
DOSAGE FORM AND USE OF DIETHYLSTILBESTROL FOR TREATING PROSTATE CANCER OR BREAST CANCER 2012
  • Chou Diana Shu-Lian
  • Ako Roland A.
  • Rioo Dze Pkhil
  • Chu Chun Kvong
  • Van Chzhen
RU2602296C2
GnRH ANALOGUE-CONTAINING COMPOSITIONS WITH DELAYED RELEASE 2010
  • Sherif-Shejkkh Rolan
  • Lakomb Frederik
  • Torres Sal'Gado Maria-Luisa
  • Kambriehl' Perrin
  • Kardus Malaspina Merse
  • Dias Del' Konsuehlo Isabel'
  • Montes Martin
  • Zhannero Fab'En
  • Del'Port Mari
  • Broshar Ann
  • Rishar Zhoehl'
RU2549490C2
COMBINED THERAPY FOR SKIN DISORDERS 2011
  • Fein Howard
  • Berlin Mindy B.
RU2603479C2
ABIRATERONE PRODRUGS 2020
  • Sharp Mettyu Dzh.
  • Mur Uilyam R.
RU2822219C2
METHOD FOR INDUCING SELECTIVE DRUG ABLATION OF THE PROSTATE GLAND WITHOUT NERVE DAMAGE, WHILE PRESERVING THE SEXUAL FUNCTION 2019
  • Averback, Paul
RU2776047C1
METHODS FOR ADMINISTRATION OF 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOLE-2-YL)PIPERIDINE-2,6-DIONE IN CERTAIN TYPES OF LEUKEMIA 2006
  • Zeldis Dzherom B.
RU2406501C2

RU 2 404 747 C2

Authors

Lennernas Khans

Lennernas Bo

Khugosson Jonas

Aksen Niklas

Dates

2010-11-27Published

2006-03-31Filed